Drug · CHEMBL596802
PRIDOPIDINE
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. PRIDOPIDINE. Drugs and targets, record CHEMBL596802. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL596802
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Open Targets' highest stage
- Phase 3, for 2 of its 2 diseases, from ClinicalTrials.gov and TTD
- Open Targets
Targets1
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| DRD2 | D(2) dopamine receptor | Dopamine D2 receptor modulator | MODULATOR | https://conductscience.org/library/genes/1813 |
Source ChEMBL
Diseases2
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Disease | Open Targets' stage | Stage reported by | Reports | Of them trials | Its drugs |
|---|---|---|---|---|---|
| Huntington disease | Phase 3 | ClinicalTrials.gov and TTD | 8 | 6 | https://conductscience.org/library/drugs?q=MONDO_0007739 |
| amyotrophic lateral sclerosis | Phase 3 | ClinicalTrials.gov | 3 | 3 | https://conductscience.org/library/drugs?q=MONDO_0004976 |
Source Open Targets
Trials11
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT04556656 | PRidopidine's Outcome On Function in Huntington Disease, PROOF- HD | Phase 3 | 499 | 2025-03-12 | pridopidine | Its name | ClinicalTrials.gov |
| NCT00665223 | A Study of Treatment With Pridopidine (ACR16) in Participants With Huntington's Disease | Phase 3 | 437 | 2023-08-29 | acr16 | Its name | ClinicalTrials.gov |
| NCT02006472 | A Phase 2, to Evaluating the Safety and Efficacy of Pridopidine Vs Placebo for Symptomatic Treatment in Patients With Huntington's Disease | Phase 2 | 408 | 2021-07-19 | pridopidine | Its name | ClinicalTrials.gov |
| NCT02494778 | A Study Evaluating if Pridopidine is Safe, Efficacious, and Tolerable in Patients With Huntington's Disease | Phase 2 | 248 | 2021-09-17 | pridopidine | Its name | ClinicalTrials.gov |
| NCT00724048 | A Study of Pridopidine (ACR16) for the Treatment of Participants With Huntington's Disease | Phase 2 | 227 | 2023-08-31 | acr16 | Its name | ClinicalTrials.gov |
| NCT04615923 | HEALEY ALS Platform Trial - Regimen D Pridopidine | Phase 2/3 | 163 | 2023-08-23 | pridopidine | Its name | ClinicalTrials.gov |
| NCT01306929 | Open-label Extension Study of Pridopidine (ACR16) in the Symptomatic Treatment of Huntington Disease | Phase 2 | 134 | 2022-02-09 | pridopidine | Its name | ClinicalTrials.gov |
| NCT03019289 | A Study to Evaluate Sigma-1 and Dopamine-2 Receptor Occupancy by Pridopidine in the Human Brain of Healthy Volunteers and in Patients With Huntington's Disease | Phase 1 | 23 | 2021-11-16 | pridopidine | Its name | ClinicalTrials.gov |
| NCT03922711 | A Study to Assess the Safety and Effectiveness of Pridopidine Compared to Placebo in the Treatment of Levodopa-Induced Dyskinesia in Patients With Parkinson's Disease | Phase 2 | 23 | 2022-07-01 | pridopidine | Its name | ClinicalTrials.gov |
| NCT07322003 | Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS | Phase 3 | 500 | pridopidine | Its name | ClinicalTrials.gov |
1 to 10 of 11
See all 11 trialsComparisons in its trials6
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Pridopidine vs Placebo: deaths from any cause | 4 of 250 | 1 of 249 | 499 | NCT04556656 | Trial comparisons |
| Pridopidine vs Placebo: serious adverse events | 34 of 250 | 21 of 249 | 499 | NCT04556656 | Trial comparisons |
| Pridopidine vs Matching Placebo: Number of Participants That Experienced Death or Death Equivalent | 5 of 120 | 6 of 162 | 282 | NCT04615923 | Trial comparisons |
| Pridopidine vs Matching Placebo: deaths from any cause | 2 of 120 | 0 of 42 | 162 | NCT04615923 | Trial comparisons |
| Pridopidine vs Matching Placebo: serious adverse events | 16 of 121 | 3 of 41 | 162 | NCT04615923 | Trial comparisons |
| Pridopidine 45 mg BID vs Placebo: Total Functional Capacity Responder Rate in Early HD | 30 of 37 | 20 of 41 | 78 | NCT02006472 | Trial comparisons |
Papers from its trials11
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
| PMID | Listed as | Trials listing it | Source |
|---|---|---|---|
| 42912861 | DERIVED | 1 | PubMed |
| 41406304 | DERIVED | 1 | PubMed |
| 40913168 | DERIVED | 1 | PubMed |
| 40067755 | DERIVED | 1 | PubMed |
| 36811812 | DERIVED | 3 | PubMed |
| 31356217 | DERIVED | 1 | PubMed |
| 30776019 | DERIVED | 1 | PubMed |
| 30572891 | DERIVED | 1 | PubMed |
| 30563778 | DERIVED | 1 | PubMed |
| 28826192 | DERIVED | 1 | PubMed |
1 to 10 of 11
See all 11 papers from its trialsTests in its trials2
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
| Test | Trials naming it as an outcome | As a primary outcome | Source |
|---|---|---|---|
| Stroop Color-Word Test | 2 | 0 | ConductCognition |
| Symbol Coding | 1 | 0 | ConductCognition |
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL596802
GET https://conductscience.org/api/drugs/v1/CHEMBL596802/targets